Ability Pharma closed a €2 million capital round through the crowdfunding platform Capital Cell.
Ability Pharma, a Barcelona, Spain-based clinical-stage biopharmaceutical company, announced securing a funding round of €2 million ($2.4M).
The money was raised via an equity crowdfudning campaign on Capital Cell. The operation has been led by an industrial partner and a business angel, both from the pharmaceutical sector, and between the two they have invested around € 350,000. The company's shareholders also include its founders and private investors, and it has the financial support of Acció (Generalitat de Catalunya) and the European Commission (EIC Accelerator), among others.
Ability Pharma, founded in 2009 by CEO Carles Domènech, is a clinical-stage biopharmaceutical company aiming to develop first-in-class therapies that address unmet medical needs in the oncology space. The company's product, ABTL0812, is in phase 2 clinical trials, as it is focused on improving the future of oncology by developing innovative therapies that address unmet medical needs.